These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38379385)

  • 1. Proteomic, miRNA and bacterial biomarker patterns in atopic dermatitis patients and their course upon anti-IL-4Rα therapy.
    Pažur K; Francuzik W; El-Mahmoud H; Kraft M; Worm M
    J Eur Acad Dermatol Venereol; 2024 Feb; ():. PubMed ID: 38379385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
    Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
    Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
    He H; Olesen CM; Pavel AB; Clausen ML; Wu J; Estrada Y; Zhang N; Agner T; Guttman-Yassky E
    Front Immunol; 2020; 11():1768. PubMed ID: 32849633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab.
    Mikhaylov D; Del Duca E; Olesen CM; He H; Wu J; Ungar B; Estrada Y; Zhang N; Chowdhury M; Clausen ML; Krueger JG; Pavel AB; Agner T; Guttman-Yassky E
    Dermatitis; 2021 Oct; 32(1S):S71-S80. PubMed ID: 34405829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
    Hamilton JD; Suárez-Fariñas M; Dhingra N; Cardinale I; Li X; Kostic A; Ming JE; Radin AR; Krueger JG; Graham N; Yancopoulos GD; Pirozzi G; Guttman-Yassky E
    J Allergy Clin Immunol; 2014 Dec; 134(6):1293-1300. PubMed ID: 25482871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Wu Y; Gu C; Wang S; Yin H; Qiu Z; Luo Y; Li Z; Wang C; Yao X; Li W
    Br J Dermatol; 2023 Apr; 188(5):649-660. PubMed ID: 36756674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atopic Dermatitis: Striving for Reliable Biomarkers.
    Mastraftsi S; Vrioni G; Bakakis M; Nicolaidou E; Rigopoulos D; Stratigos AJ; Gregoriou S
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.
    Brunner PM; Suárez-Fariñas M; He H; Malik K; Wen HC; Gonzalez J; Chan TC; Estrada Y; Zheng X; Khattri S; Dattola A; Krueger JG; Guttman-Yassky E
    Sci Rep; 2017 Aug; 7(1):8707. PubMed ID: 28821884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice.
    Kishi R; Toyama S; Tominaga M; Kamata Y; Komiya E; Kaneko T; Suga Y; Takamori K
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.
    Kamata M; Tada Y
    JID Innov; 2021 Sep; 1(3):100042. PubMed ID: 34909737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin.
    Leung DYM; Bissonnette R; Kreimer S; Berdyshev E; Bafna S; Lyubchenko T; Richers BN; Garcia S; Ramirez-Gama M; Hall CF; Xiao O; Taylor P; Boguniewicz M; Levit NA; Agueusop I; Zhang A; Goleva E
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1421-1428. PubMed ID: 36958520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
    Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
    J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.
    Brunner PM; He H; Pavel AB; Czarnowicki T; Lefferdink R; Erickson T; Canter T; Puar N; Rangel SM; Malik K; Estrada Y; Krueger JG; Guttman-Yassky E; Paller AS
    J Am Acad Dermatol; 2019 Aug; 81(2):510-519. PubMed ID: 31009665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in allergen-specific basophil activation and T cell proliferation in atopic dermatitis patients with comorbid allergic rhinoconjunctivitis treated with a monoclonal anti-IL-4Rα antibody or allergen-specific immunotherapy.
    Layritz AS; Galicia-Carreón J; Benfadal S; Novak N
    Immun Inflamm Dis; 2023 Apr; 11(4):e808. PubMed ID: 37102639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic signatures of inflammatory skin diseases: a focus on atopic dermatitis.
    Mikhaylov D; Del Duca E; Guttman-Yassky E
    Expert Rev Proteomics; 2021 May; 18(5):345-361. PubMed ID: 34033497
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
    Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Alters Both the Bacterial and Fungal Skin Microbiomes of Patients with Atopic Dermatitis.
    Umemoto N; Kakurai M; Matsumoto T; Mizuno K; Cho O; Sugita T; Demitsu T
    Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38276210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-4Rα signalling in B cells and T cells play differential roles in acute and chronic atopic dermatitis.
    Scibiorek M; Mthembu N; Mangali S; Ngomti A; Ikwegbue P; Brombacher F; Hadebe S
    Sci Rep; 2023 Jan; 13(1):144. PubMed ID: 36599893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.